This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ImmunoGen, Inc. Announces Clinical Data Presentations At Upcoming 50th Annual Meeting Of ASCO

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today provided information on the data presentations on Company and partner compounds to be made at the 2014 American Society of Clinical Oncology (ASCO) annual meeting, which will be held May 30-June 3 in Chicago, IL. New clinical data are being presented on ImmunoGen wholly owned compounds, IMGN529 and IMGN853, as well as on partner compounds SAR3419, SAR650984 and Kadcyla ® (ado-trastuzumab emtansine).

The presentations on our wholly owned product candidates reflect the unique and promising profile of these compounds as well as our strengthened drug development capabilities,” commented Daniel Junius, President and CEO. “At the same time, the presentations on partner compounds add to the growing body of data on the importance of these compounds.”

IMGN529

Poster presentation: Friday, May 30, 1:00-4:00pm CT; Lymphoma and Plasma Cell Disorders Poster Highlights Session, S405, poster board #6. Abstract #8526: "Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL)."

IMGN529 contains a CD37-targeting antibody that demonstrates pronounced activity against CD37-positive cancer cells in preclinical models with the potent cytotoxic agent, DM1, attached. It is currently in dose-finding Phase I clinical testing for the treatment of NHL; its maximum-tolerated dose (MTD) is not yet established.

The data made public today in the abstract include that patient dosing with IMGN529 began at 0.1 mg/kg, administered once every three weeks, with new cohorts of patients receiving progressively higher dose levels up to 0.8 mg/kg. As the Company disclosed late last year, biological changes were unexpectedly observed at these low doses.

As reported in the abstract, these included the occurrence of Grade 3 or 4 asymptomatic neutropenia or febrile neutropenia in 5 and 2, respectively, of the 18 patients enrolled. The biological changes also included a post-dosing reduction in lymphocytes, consistent with IMGN529’s anticancer mechanism of action. Additionally, 2 patients had partial remissions (PRs): a patient with follicular lymphoma treated at 0.2 mg/kg and a patient with diffuse large B-cell lymphoma treated at 0.4 mg/kg.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,794.81 -133.39 -0.74%
S&P 500 2,071.27 -18.19 -0.87%
NASDAQ 4,896.6750 -42.6520 -0.86%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs